BNP Paribas Financial Markets Raises Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

BNP Paribas Financial Markets lifted its position in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 220.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 43,813 shares of the company's stock after purchasing an additional 30,160 shares during the period. BNP Paribas Financial Markets owned about 0.14% of Fulgent Genetics worth $952,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in FLGT. Asset Dedication LLC bought a new position in shares of Fulgent Genetics in the second quarter worth approximately $33,000. nVerses Capital LLC bought a new position in shares of Fulgent Genetics in the second quarter worth approximately $43,000. Signaturefd LLC boosted its holdings in Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company's stock valued at $44,000 after acquiring an additional 1,132 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Fulgent Genetics in the second quarter valued at $63,000. Finally, Gladius Capital Management LP bought a new stake in Fulgent Genetics in the third quarter valued at $81,000. Institutional investors own 48.06% of the company's stock.

Fulgent Genetics Trading Down 0.5 %

Fulgent Genetics stock traded down $0.10 on Wednesday, hitting $20.13. 160,679 shares of the stock traded hands, compared to its average volume of 189,353. The firm has a market cap of $615.78 million, a P/E ratio of -3.65 and a beta of 1.42. The business's fifty day simple moving average is $19.59 and its 200 day simple moving average is $21.01. Fulgent Genetics, Inc. has a 1 year low of $16.56 and a 1 year high of $30.68.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Piper Sandler cut their price target on shares of Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating on the stock in a report on Monday, November 11th. StockNews.com cut shares of Fulgent Genetics from a "hold" rating to a "sell" rating in a report on Wednesday, November 27th.

Insider Buying and Selling at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,227 shares of Fulgent Genetics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $40,665.02. Following the completion of the transaction, the chief executive officer now owns 703,711 shares of the company's stock, valued at $12,849,762.86. The trade was a 0.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 3,413 shares of company stock valued at $62,321. 32.66% of the stock is currently owned by company insiders.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.